Rubraca (rucaparib)

January 16, 2020January 16, 2020

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review status ... Read more

August 7, 2017

BMS and Clovis to Study Opdivo, Rubraca Combo Treatment in Prostate, Other Cancers

News

Bristol-Myers Squibb and Clovis Oncology will collaborate to assess the combination of Opdivo (nivolumab) and Rubraca (rucaparib) in Phase 2 and 3 clinical studies in patients with different cancer types, including ... Read more

February 7, 2017

Strata to Help Clovis Find Patients for Prostate Cancer Trials of Rucaparib

News

Strata Oncology will help Clovis Oncology accelerate patient enrollment in ongoing clinical trials assessing Clovis’ rucaparib as a treatment for metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA or ATM mutations. Strata is conducting ... Read more